Main Menu

The United States Patent and Trademark Office (USPTO) recognized NIAID TTIPO’s public health-centered patent management efforts with the Patents for Humanity: COVID-19 category award with the USPTO announcing the award on December 15, 2022. NIAID, Scripps Research Institute, and Dartmouth College invented stabilized coronavirus spike proteins, which were essential to the development of the COVID-19 vaccines used today. The vaccines that incorporate these stabilized spike proteins have been instrumental in combating the COVID-19 pandemic.

Rotavirus is a disease that affects nearly every child worldwide. While most cases have mild symptoms, it is responsible for one third of infant hospitalizations for severe diarrhea and kills an estimated 200,000 children a year, mostly in developing countries. Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH) developed vaccine formulations to address the six most common forms of rotavirus.

Rotavirus is a disease that affects nearly every child worldwide. While most cases have mild symptoms, it is responsible for one third of infant hospitalizations for severe diarrhea and kills an estimated 200,000 children a year, mostly in developing countries. Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH) developed vaccine formulations to address the six most common forms of rotavirus.

Human papilloma virus (HPV) is the most common sexually transmitted infection in the United States. The Centers for Disease Control and Prevention estimates that about 6.2 million Americans are infected with genital HPV each year and that over half of all sexually active men and women become infected at some time in their lives. While most HPV infections are cleared by the body’s own defense system and do not lead to cancer, virtually all cases of cervical cancer are linked to HPV infection.

BIO 2007 Innovation Corridor “Best Poster” Award

The poster presented by Anna Z. Amar, Technology Development Associate, National Institute of Allergy and Infectious Diseases (NIAID), NIH – for a Novel Protein for Development of a Chlamydial Vaccine – was awarded “Best Poster” at the BIO 2007 Convention. 

Prostate cancer is the most common non-skin cancer of males in the U.S., and is responsible for more deaths than any other cancer, except lung cancer. Cancer vaccines, which harness the body’s immune system to identify and destroy cancer cells, have emerged as a promising new approach to fighting prostate cancer. One approach to cancer vaccination involves identifying antigens from cancer cells and immunizing cancer patients against those antigens to stimulate the body’s immune cells to attack and kill the cancer cells. 

Meningococcal meningitis, a bacterial infection of the brain that sweeps across sub-Saharan Africa in an area called the “meningitis belt,” is now losing its power to inflict illness and death. Scientists and technology transfer officers from the U.S.

This 2014 Deals of Distinction™ Award from the LES Industry-University-Government Interface Sector (IUGI) went to the U.S. Food and Drug Administration (FDA), along with the National Institutes of Health (NIH), PATH, and the Serum Institute of India (SII) for MenAfriVac, a low-cost meningitis vaccine designed for use in sub-Saharan Africa.

Cancer vaccines harness the immune system to identify and destroy cancer cells, and are a promising new approach to fighting cancer. In contrast to preventative vaccines, cancer vaccines identify antigens from cancer cells and immunize cancer patients against those antigens to stimulate the body’s immune cells to attack and kill the cancer cells. The National Cancer Institute (NCI) has developed investigational cancer vaccines that induct a specific, targeted immune response against cancer cells expressing the brachyury protein.

Cancer vaccines harness the immune system to identify and destroy cancer cells, and are a promising new approach to fighting cancer. In contrast to preventative vaccines, cancer vaccines identify antigens from cancer cells and immunize cancer patients against those antigens to stimulate the body’s immune cells to attack and kill the cancer cells. The National Cancer Institute (NCI) has developed investigational cancer vaccines that induce a specific, targeted immune response against cancer cells expressing the brachyury protein.